Compare Expedia Group Inc (EXPE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Tango Therapeutics Inc. — how do they compare? Expedia Group Inc trades at $275.05 (market cap $32.82B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Expedia Group Inc is far larger — about 8.8× Tango Therapeutics Inc.'s market cap, and Expedia Group Inc pays a 0.7% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Tango Therapeutics Inc. for 0 Days on average.
| EXPE | TNGX | |
|---|---|---|
Market Cap | $32.82B | $3.75B |
Volume | 1,337,882 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $32.90 |
52-Week Low | $188.51 | $7.50 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.38B | $2.77B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.69, up 2.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 17.2, net income margin of 12.97%, and positive cash flow trends. Recent news highlights competitive threats from AI agents but also underscores Expedia's growth in B2B bookings and strategic partnerships.
The outlook for EXPE is positive, supported by earnings momentum and a consensus price target of $335.06, though risks include AI disruption and competitive pressures. Revenue growth and margin expansion present opportunities, but investor caution is warranted given mixed analyst ratings and market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
